MARKET

EIGR

EIGR

Eiger Biopharma
NASDAQ
0.3401
-0.0049
-1.42%
After Hours: 0.3400 -0.0001 -0.03% 16:09 11/30 EST
OPEN
0.3250
PREV CLOSE
0.3450
HIGH
0.3600
LOW
0.3234
VOLUME
309.69K
TURNOVER
0
52 WEEK HIGH
4.620
52 WEEK LOW
0.2100
MARKET CAP
15.10M
P/E (TTM)
-0.1735
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers avidity biosciences (nasdaq:rna) shares rose 38.1% to $8.51 during tuesday's pre-market session. Heart test laboratories shares moved upwards by 22.98%. Icad shares increased by 17.51% and senestech stock decreased by 38.3%. Tharimmune stock fell 69.5% during the session.
Benzinga · 2d ago
Weekly Report: what happened at EIGR last week (1120-1124)?
Weekly Report · 3d ago
Eiger Biopharma: General statement of acquisition of beneficial ownership
Press release · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.
Benzinga · 11/22 21:31
Dow Surges 150 Points; US Jobless Claims Decline Sharply
The dow jones index traded up 150 points on wednesday. The nasdaq and s&p 500 also traded higher. U.s. Initial jobless claims declined by 24,000 to 209,000 in the week ending nov. 18. Agilethought, inc. Shares shot up 129% after climbing 5% on tuesday.
Benzinga · 11/22 14:43
Weekly Report: what happened at EIGR last week (1113-1117)?
Weekly Report · 11/20 10:53
Eiger Biopharma: Current report
Press release · 11/13 21:09
Weekly Report: what happened at EIGR last week (1106-1110)?
Weekly Report · 11/13 10:47
More
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

Webull offers Eiger Biopharmaceuticals Inc stock information, including NASDAQ: EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.